Author

Vipul Jairath

Shaping immunity: Innovation trials in IBD
Shaping immunity: Innovation trials in IBD

Vipul Jairath

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Vipul Jairath  et al.

IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36
IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36

Vipul Jairath  et al.

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Vipul Jairath  et al.

IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36
IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Vipul Jairath  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Vipul Jairath  et al.

IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Vipul Jairath  et al.

A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE
A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE

Vipul Jairath  et al.

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Vipul Jairath  et al.

INTRAVENOUS USTEKINUMAB REINDUCTION IS EFFECTIVE IN PRIOR BIOLOGIC REFRACTORY PATIENTS WITH CROHN'S DISEASE ALREADY ON 4 WEEKLY DOSING: A REAL-WORLD CASE SERIES
INTRAVENOUS USTEKINUMAB REINDUCTION IS EFFECTIVE IN PRIOR BIOLOGIC REFRACTORY PATIENTS WITH CROHN'S DISEASE ALREADY ON 4 WEEKLY DOSING: A REAL-WORLD CASE SERIES

Vipul Jairath  et al.

A NOVEL STIFFENING WIRE INCREASES THE DEPTH OF INSERTION DURING DOUBLE BALLOON ENTEROSCOPY – FINDINGS FROM A SINGLE BLIND RANDOMIZED CONTROLLED TRIAL​​​​
A NOVEL STIFFENING WIRE INCREASES THE DEPTH OF INSERTION DURING DOUBLE BALLOON ENTEROSCOPY – FINDINGS FROM A SINGLE BLIND RANDOMIZED CONTROLLED TRIAL​​​​

Vipul Jairath  et al.

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Vipul Jairath  et al.

​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW
​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW

Vipul Jairath  et al.

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Vipul Jairath  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Vipul Jairath  et al.

THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE
THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE

Vipul Jairath  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Vipul Jairath  et al.

Item 1 - 20 / 30
1
2